Stockscreener 앱 받기
31.90
3.09%
-1.12
전일 마감가:
$33.02
열려 있는:
$33.07
하루 거래량:
307.09K
Relative Volume:
0.39
시가총액:
$2.99B
수익:
$4.72M
순이익/손실:
$-277.91M
주가수익비율:
-8.5523
EPS:
-3.73
순현금흐름:
$-203.56M
1주 성능:
+0.22%
1개월 성능:
+4.92%
6개월 성능:
-14.32%
1년 성능:
-38.94%
1일 변동 폭
$31.90
$33.22
1주일 범위
$31.42
$33.49
52주 변동 폭
$24.10
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
명칭
Crinetics Pharmaceuticals Inc
전화
858-450-6464
주소
6055 LUSK BLVD., SAN DIEGO, CA
CRNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
31.90 | 3.00B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.34 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.47 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.91 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.13 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 개시 | Goldman | Neutral |
| 2025-03-25 | 개시 | Stifel | Buy |
| 2025-02-11 | 개시 | TD Cowen | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Peer Perform |
| 2025-01-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-01-16 | 개시 | Morgan Stanley | Overweight |
| 2023-12-21 | 개시 | Jefferies | Hold |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-31 | 개시 | Oppenheimer | Outperform |
| 2023-04-24 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Robert W. Baird | Outperform |
| 2021-11-30 | 개시 | JMP Securities | Mkt Outperform |
| 2021-11-23 | 개시 | Evercore ISI | Outperform |
| 2021-06-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-23 | 개시 | ROTH Capital | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2018-08-13 | 개시 | JP Morgan | Neutral |
| 2018-08-13 | 개시 | Leerink Partners | Outperform |
| 2018-08-13 | 개시 | Piper Jaffray | Overweight |
모두보기
Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스
What drives Crinetics Pharmaceuticals Inc. stock priceExceptional risk-adjusted gains - Jammu Links News
Crinetics Pharmaceuticals’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Crinetics stock maintains Buy rating at Jones Trading on positive ENDO’25 data - Investing.com Canada
Crinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs - Insider Monkey
what makes crinetics pharmaceuticals inc. stock price move sharplySafer Investing With Bigger Upside - Newser
What makes Crinetics Pharmaceuticals Inc. stock price move sharplyFree Wealth-Building Investment Strategies - Newser
Why Crinetics Pharmaceuticals Inc. stock attracts strong analyst attentionFree Investment Community - Newser
How Crinetics Pharmaceuticals Inc. stock performs during market volatilityChart Based Entries - Newser
JMP reiterates Market Outperform rating on Crinetics stock as paltusotine shows strong data - Investing.com Nigeria
Teacher Retirement System of Texas Sells 1,561 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly - Benzinga
Crinetics reveals new data from acromegaly therapy programme - Yahoo
New data for oral acromegaly drug ahead of approval decision - The Pharma Letter
Acromegaly's Next Frontier: Crinetics' PALSONIFY Aims to Overhaul Treatment Standards - AInvest
Crinetics Pharmaceuticals New Data Show Durable Control of Palsonify in Acromegaly - MarketScreener
CRNX to Highlight PALSONIFY Data at ENDO 2025 | CRNX Stock News - GuruFocus
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025 - The Manila Times
Crinetics Pharmaceuticals Presents New Long-Term Data on PALSONIFY for Acromegaly at ENDO 2025 - Quiver Quantitative
Crinetics to Present New Long-Term Data Demonstrating Durable Co - GuruFocus
Amalgamated Bank Boosts Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
The Goldman Sachs Group Initiates Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financia - GuruFocus
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 - Yahoo Finance
Goldman Sachs initiates coverage on Crinetics stock with Neutral rating By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants - GuruFocus
Crinetics Expands Team with 46 New Hires, Grants $3.2M+ in Equity Compensation - Stock Titan
Goldman Sachs Initiates Crinetics Pharmaceuticals at Neutral With $36 Price Target - MarketScreener
Goldman Sachs Begins Coverage of Crinetics (CRNX) with Neutral O - GuruFocus
Should You Hold Crinetics Pharmaceuticals (CRNX)? - Insider Monkey
KBC Group NV Grows Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Hyperparathyroidism Pipeline 2025: Groundbreaking Clinical - openPR.com
Crinetics Pharmaceuticals’ SWOT analysis: stock poised for growth in endocrine treatments - Investing.com Australia
Crinetics Pharmaceuticals’ SWOT analysis: stock poised for growth in endocrine treatments By Investing.com - Investing.com South Africa
Contrasting Crinetics Pharmaceuticals (NASDAQ:CRNX) & Vaxart (NASDAQ:VXRT) - Defense World
Crinetics stock rating reiterated at Market Outperform by JMP ahead of key data - Investing.com Canada
Crinetics to Showcase the Next Generation of Endocrinology Innov - GuruFocus
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline - TradingView
New Oral Treatment Breakthrough: Crinetics Reveals Long-Term Success Data for Acromegaly Drug at ENDO 2025 - Stock Titan
Crinetics Pharmaceuticals’ (CRNX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Crinetics Pharmaceuticals (CRNX) Stock Update: Analyst Maintains - GuruFocus
Crinetics Pharmaceuticals (CRNX) Stock Update: Analyst Maintains 'Buy' Rating | CRNX Stock News - GuruFocus
GAMMA Investing LLC Has $227,000 Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Trading (CRNX) With Integrated Risk Controls - news.stocktradersdaily.com
Crinetics to Unveil Critical Pipeline Updates: New Data on NETs, Graves Disease, and Kidney Disease Programs - Stock Titan
Crinetics Pharmaceuticals: Highly Priced Biotech Awaits PDUFA On Acromegaly Drug - Seeking Alpha
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025 - The Manila Times
Rhumbline Advisers Increases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Research Analysts Offer Predictions for CRNX FY2026 Earnings - Defense World
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants - GuruFocus
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CRNX Stock News - GuruFocus
Crinetics Pharmaceuticals Inc (CRNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Crinetics Pharmaceuticals Inc 주식 (CRNX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Betz Stephen F. | Chief Scientific Officer |
Jun 12 '25 |
Sale |
32.23 |
97,483 |
3,141,877 |
99,713 |
0.86%
0.10%
자본화:
|
볼륨(24시간):